virtual screening

Acheminall Corporation works on drug discovery and development of small molecule therapeutics to treat schistosomiasis and breast cancer. Its work includes computer-aided drug design, photoreactive chemical probes, target engagement, small molecule drug design, synthetic organic chemistry, and virtual screening.

computer-aided drug designphotoreactive chemical probessmall molecule drug designsynthetic organic chemistrytarget engagement

ARIScience uses its AI+QQ process, unifying AI, quantum chemistry, computer vision, and biochemistry, to design and discover small molecule compounds that interrupt disease pathways. It pursues treatments for neurodegenerative, inflammatory, and infectious diseases, and was awarded a BARDA small molecule research contract in April 2023, completed in October 2024.

AI and quantum chemistry (AI+QQ) in silico drug discoveryin vitro assays (FRET, thermal shift, ITC)in vivo murine model confirmation via CROsmachine learningmolecular modeling

ChemDiv is a fully integrated target-to-clinic contract research organization (CRO) that has worked for over 32 years on drug discovery programs for cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners. It offers integrated drug discovery services including custom chemistry, HTS, CADD, ADME, DMPK, discovery biology and preclinical services.

ADME/DMPK testinganimal modelscombinatorial chemistrycustom chemistryhigh throughput screening (HTS)in silico drug design (CADD)in vitro assaysin vivo studieslibrary designmedicinal chemistrymolecular dockingmolecular dynamicspharmacokinetic studiestoxicology studies

Chemestmed is an Estonian biotech company developing first-in-class drugs to treat CNS and metabolic diseases and disorders. It works in epitranscriptomics, developing a technological platform for discovery of novel drugs based on mRNA regulation in cells, including small-molecule activators targeting the METTL3/METTL14 methyltransferase complex to enhance RNA m⁶A methylation.

cell-based assay developmentCRISPR/Cas9 gene editingenzyme assaysepitranscriptomics researchin vitro cell culturemolecular modelingNMR analysisorganic synthesisquantum chemistry calculationssmall molecule drug discovery

Denovo Sciences builds AI-powered technologies for first-principles, structure-based small-molecule drug discovery. Its proprietary platform selects optimal target conformations, designs molecules de novo inside the binding pocket, and prioritizes drug-like, synthetically accessible candidates. The company reports 6 drug discovery programs, 300+ tested AI-generated molecules, and a 30% average hit rate.

ADMET property evaluationAI-powered drug discoveryde novo molecule generationprotein binding site evaluationstructure-based drug designsynthetic route prediction

Enamine is a chemistry research organization and CRO that has been accumulating chemical knowledge and experience since 1991. It provides integrated drug discovery services, compound library synthesis, custom synthesis, FTE chemistry support, CADD, biology, and hit follow-up support, backed by over 650 chemists and the world's largest collection of building blocks.

1H NMRADMET profilingasymmetric synthesiscustom synthesiselectrochemistryfluorination with SF4free energy perturbationhigh-pressure hydrogenationHTSLCMS quality controllibrary synthesismolecular dockingmolecular dynamicsparallel synthesisphotochemistry in flowQSAR modelingreversed-phase preparative HPLC purification